Author(s):
Sushant M. Ahire, Prerana S. Pawar, Sunil K. Mahajan
Email(s):
sushantahire071@gmail.com
DOI:
10.52711/2321-5836.2026.00022 
Address:
Sushant M. Ahire1, Prerana S. Pawar2, Sunil K. Mahajan1
1Department of Pharmaceutical Chemistry, Divine College of Pharmacy, Satana, Nashik, Maharashtra, India.
2Department of Pharmaceutics, Divine College of Pharmacy, Satana, Nashik, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 2,
Year - 2026
ABSTRACT:
GBS is a rare but serious neurological disorder in which the immune system mistakenly targets the nerves, causing muscle weakness, tingling, and, in severe cases, paralysis. First identified in 1916, GBS has several variations, including acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and Miller Fisher Syndrome (MFS). Although its exact cause remains unclear, it is often triggered by infections, vaccinations, surgery, or autoimmune conditions. The disorder disrupts nerve communication by damaging either the protective myelin sheath or the nerve fibres themselves, leading to motor and autonomic dysfunction. Diagnosis is based on symptoms, cerebrospinal fluid analysis, and nerve studies. Treatment primarily involves modulating the immune response through intravenous immunoglobulin (IVIG) or plasma exchange, along with supportive care and rehabilitation. While most individuals recover within a year, some may experience persistent weakness or complications. Advances in medical research have significantly improved recovery rates, but further studies are needed to enhance understanding and prevention of the condition.
Cite this article:
Sushant M. Ahire, Prerana S. Pawar, Sunil K. Mahajan. Guillain-Barre Syndrome: A Review. Sushant M. Ahire, Prerana S. Pawar, Sunil K. Mahajan. Research Journal of Pharmacology and Pharmacodynamics.2026;18(2):159-4. doi: 10.52711/2321-5836.2026.00022
Cite(Electronic):
Sushant M. Ahire, Prerana S. Pawar, Sunil K. Mahajan. Guillain-Barre Syndrome: A Review. Sushant M. Ahire, Prerana S. Pawar, Sunil K. Mahajan. Research Journal of Pharmacology and Pharmacodynamics.2026;18(2):159-4. doi: 10.52711/2321-5836.2026.00022 Available on: https://rjppd.org/AbstractView.aspx?PID=2026-18-2-7
REFERENCES:
1. Basuki M, Hamdan M, Fidiana, Fadil, Marjianto IR. Association between transmission season and degree of severity in Guillain-Barre syndrome. Res J Pharm Technol. 2020; 13(11): 5345-8.
2. Kusunoki S. [History of Guillain-Barre syndrome]. Brain Nerve. 2015 Nov; 67(11): 1295-303. Japanese.
3. Hughes RAC. Guillain-Barre syndrome: history, pathogenesis, treatment, and future directions. Eur J Neurol. 2024 Nov; 31(11): e16346.
4. Exploring the incidence and the effectiveness of structured teaching programme on minor disorders of pregnancy and its management among primigravida mothers in a selected rural area in Dharmapuri Dt. Asian J Nurs Educ Res. 2015; 5(1): 118-20.
5. Torres-Vásquez M, Chávez-Bosquez O, Hernández-Ocaña B, Hernández-Torruco J. Classification of Guillain-Barre syndrome subtypes using sampling techniques with binary approach. Symmetry. 2020; 12(3): 482.
6. Gautam H, Kutlehria A, Katoch K, Verma KK. Rhabdoviruses: complex neuropathogenic mechanism, molecular virology, epidemiology and treatment. Asian J Pharm Technol. 2024; 14(1): 59-64.
7. Bellanti R, Rinaldi S. Guillain-Barre syndrome: a comprehensive review. Eur J Neurol. 2024 Aug; 31(8): e16365.
8. Abbassi N, Ambegaonkar G. Guillain-Barre syndrome: a review. Paediatr Child Health. 2019; 29(11): 459-62.
9. Khan SA, Das PR, Nahar Z, Dewan SMR. An updated review on Guillain-Barre syndrome: challenges in infection prevention and control in low- and middle-income countries. SAGE Open Med. 2024; 12: 20503121241239633.
10. Jadhav SP, Ahire SM, Shewale VV, Patil CD, Pagar RY, Sonawane DD, Mahajan SK. Formulation of Tablet of Nifedipine co-crystal for enhancement of solubility and other physical properties. Biotech Res Asia. 2025 Mar 25; 22(1): 191-200.
11. Laman JD, Huizinga R, Boons GJ, Jacobs BC. Guillain-Barre syndrome: expanding the concept of molecular mimicry. Trends Immunol. 2022 Apr; 43(4): 296-308.
12. Dimachkie MM, Barohn RJ. Guillain-Barre syndrome and variants. Neurol Clin. 2013 May; 31(2): 491-510.
13. Chung T, Prasad K, Lloyd TE. Peripheral neuropathy: clinical and electrophysiological considerations. Neuroimaging Clin N Am. 2014 Feb; 24(1): 49-65.
14. Podbielska M, Banik NL, Kurowska E, Hogan EL. Myelin recovery in multiple sclerosis: the challenge of remyelination. Brain Sci. 2013 Aug; 3(3): 1282-324.
15. Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barre syndrome. Hum Vaccin Immunother. 2018; 14(11): 2568-79.
16. Rajabally YA. Immunoglobulin and monoclonal antibody therapies in Guillain-Barre syndrome. Neurotherapeutics. 2022; 19(3): 885-96.
17. Pawar PS, Ahire SM, Shewale VV, Jadhav S, Mahajan SK, Sonawane DD. Silver Nanoparticles: A Comprehensive Review on Synthesis, Properties and Applications. Research Journal of Pharmaceutical Dosage Forms and Technology. 2025 Nov 3; 17(4): 279-85.
18. Susila C. A qualitative assessment on issues among nurses directly involved with women who choose to terminate their pregnancy. Asian J Nurs Educ Res. 2012; 2(3): 107-8.
19. Morell P, Quarles RH. The myelin sheath. In: Siegel GJ, Agranoff BW, Albers RW, et al., editors. Basic neurochemistry: molecular, cellular and medical aspects. 6th ed. Philadelphia (PA): Lippincott-Raven; 1999.
20. Ahire SM, Pawar PS, Sonawane VN, Jadhav SP. Personalized Medicine and Pharmacogenomics: Impact of Genetic variation on Drug Response and Individualized Therapy-A Review. Asian Journal of Pharmacy and Technology. 2026 Jan 27; 16(1): 91-8.
21. Dimachkie MM, Barohn RJ. Guillain-Barre syndrome and variants. Neurol Clin. 2013 May; 31(2): 491-510.
22. Ziganshin RH, Ivanova OM, Lomakin YA, Belogurov AA Jr, Kovalchuk SI, Azarkin IV, et al. The pathogenesis of the demyelinating form of Guillain-Barre syndrome (GBS): proteo-peptidomic and immunological profiling of physiological fluids. Mol Cell Proteomics. 2016 Jul; 15(7): 2366-78.
23. Chang CWJ. Myasthenia gravis and Guillain-Barre syndrome. In: Parrillo JE, Dellinger RP, editors. Critical care medicine: principles of diagnosis and management in the adult. 5th ed. Philadelphia (PA): Elsevier; 2019. p. 1061-74.
24. Katirji B. Disorders of peripheral nerves. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, editors. Bradley and Daroff's neurology in clinical practice. 8th ed. Philadelphia (PA): Elsevier; 2022. Chap 106.
25. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011; 36(2): 123-33.
26. Gautam H, Kutlehria A, Katoch K, Verma KK. Rhabdoviruses: complex neuropathogenic mechanism, molecular virology, epidemiology and treatment. Asian J Pharm Technol. 2024; 14(1): 59-64.